Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

HemaSphere·2026

Same author

Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia.

Annals of hematology·2026

Same author

Ensemble threshold Boolean modeling reveals robust attractors and regulatory drivers in pediatric leukemia.

Computers in biology and medicine·2026

Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Same author

IGFBP-6 as a potential therapeutic target in musculoskeletal disorders.

Expert opinion on therapeutic targets·2026

Same author

Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.

British journal of haematology·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

BRAF mutations in hairy-cell leukemia.

Enrico Tiacci¹, Vladimir Trifonov, Gianluca Schiavoni

¹Institute of Hematology, University of Perugia, Perugia, Italy.

The New England Journal of Medicine

|June 14, 2011

Summary

The BRAF V600E mutation is present in all hairy cell leukemia (HCL) patients, indicating its role in the disease. This discovery opens avenues for targeted HCL therapies.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 11, 2026

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Area of Science:

Oncology
Genetics
Molecular Biology

Background:

Hairy cell leukemia (HCL) is a distinct hematologic malignancy.
The genetic underpinnings of HCL have remained largely unknown.

Observation:

Massively parallel sequencing of whole exomes from HCL patients identified somatic mutations.
A specific BRAF V600E mutation was consistently found in all evaluated HCL cases.

Findings:

The BRAF V600E mutation was identified in 100% of HCL patients studied, but not in other B-cell leukemias or lymphomas.
HCL cells showed constitutive activation of the RAF-MEK-ERK pathway, downstream of BRAF.
In vitro treatment with a BRAF inhibitor (PLX-4720) reduced signaling in HCL cells.

Implications:

The BRAF V600E mutation is a potential unifying genetic lesion in hairy cell leukemia.
This finding has significant implications for the diagnosis and targeted therapy of HCL.
Targeting the BRAF V600E mutation may offer a novel therapeutic strategy for HCL patients.